Prosecution Insights
Last updated: April 19, 2026
Application No. 17/852,259

SYSTEMS AND METHODS FOR DEMAND AND SUPPLY FORECASTING FOR CLINICAL TRIALS

Final Rejection §101
Filed
Jun 28, 2022
Examiner
KANAAN, MAROUN P
Art Unit
3687
Tech Center
3600 — Transportation & Electronic Commerce
Assignee
4G Clinical, LLC
OA Round
6 (Final)
62%
Grant Probability
Moderate
7-8
OA Rounds
3y 6m
To Grant
94%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allow Rate
437 granted / 701 resolved
+10.3% vs TC avg
Strong +32% interview lift
Without
With
+32.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
31 currently pending
Career history
732
Total Applications
across all art units

Statute-Specific Performance

§101
34.6%
-5.4% vs TC avg
§103
35.8%
-4.2% vs TC avg
§102
18.6%
-21.4% vs TC avg
§112
7.0%
-33.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 701 resolved cases

Office Action

§101
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION DETAILED ACTION Response to Amendment This action is in response to applicant arguments filled on 01/22/2026 Claims 1-20 have been previously canceled. Claims 21, 34, and 40 have been amended. Claim 42 has been added new. Claims 21-42 are presented for examination. Detailed Action Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 21-42 are rejected under 35 U.S.C. 101 because the claimed invention is directed to an abstract idea without significantly more. Step 1: The claim(s) recite(s) subject matter within a statutory category as a process (claims 21-33 and 41), machine (claims 34-39), and manufacture (claims 40) which recite steps of: (claims 21, 34, and 40) calculating a demand profile, calculating a buffer quantity, calculating a supply plan, and outputting the supply plan. Independent Claims Step 2A, Prong One: These steps of (claims 21, 34, and 40) calculating a demand profile, calculating a buffer quantity, calculating two or more confidence values, and calculating a supply plan, as drafted, under the broadest reasonable interpretation (BRI), include performance of the limitation in the mind and mathematical calculations but for recitation of generic computer components. That is, other than reciting steps as performed by the generic computer components, nothing in the claim elements precludes the steps from practically being performed in the mind. For example, but for the (claim 21) computer-implemented and processor and (claims 34 and 40) processor and storage medium language, these steps in the context of these claims encompass a mental process of the user and mathematical calculations. If a claim limitation, under its broadest reasonable interpretation, covers performance of the limitation in the mind and mathematical calculations but for the recitation of generic computer components, then it falls within the “Mental Processes” and “Mathematical Concepts” groupings of abstract ideas. Accordingly, the claims recite an abstract idea. Step 2A, Prong Two: This judicial exception is not integrated into a practical application. In particular, the additional elements do not integrate the abstract idea into a practical application, other than the abstract idea per se, because the additional elements amount to no more than limitations which: amount to mere instructions to apply an exception (such as recitation of (claim 21) computer-implemented and processor and (claims 34 and 40) processor and storage medium language; and (claims 21, 34, and 40) controlling, with a randomization and trial supply management system, distribution of the clinical supply based on the supply plan, amount to invoking computers as a tool to perform the abstract idea, see applicant’s specification Figure 8 and [0080], see MPEP 2106.05(f)). Looking at the limitations as an ordered combination adds nothing that is not already present when looking at the elements taken individually. There is no indication that the combination of elements improves the functioning of a computer or improves any other technology. Their collective functions merely provide conventional computer implementation and do not impose a meaningful limit to integrate the abstract idea into a practical application. Step 2B: The claim(s) does/do not include additional elements that are sufficient to amount to significantly more than the judicial exception. As discussed above with respect to discussion of integration of the abstract idea into a practical application, the additional elements amount to no more than mere instructions to apply an exception. Looking at the limitations as an ordered combination adds nothing that is not already present when looking at the elements taken individually. There is no indication that the combination of elements improves the functioning of a computer or improves any other technology. Their collective functions merely provide conventional computer implementation. Dependent Claims Step 2A, Prong One: Dependent claims recite additional subject matter which further narrows or defines the abstract idea embodied in the claims (such as claims 22-28, 33, and 35-42, reciting further calculations, forecasts, determinations, and comparisons, which a mental process and/or a mathematical calculation). Step 2A, Prong Two: Dependent claims recite additional subject matter which amount to limitations consistent with the additional elements in the independent claims, such as: claims 29-31, reciting NLP at such a high level as to amount to general instructions to “apply it” to the claimed invention; claim 32, reciting an RTSM system and API implementation at such a high level as to amount to general instructions to “apply it” to the claimed invention; and claim 33, reciting transmitting a notification, which are additional limitations which amount to invoking computers as a tool to perform the abstract idea Looking at the limitations as an ordered combination adds nothing that is not already present when looking at the elements taken individually. There is no indication that the combination of elements improves the functioning of a computer or improves any other technology. Their collective functions merely provide conventional computer implementation and do not impose a meaningful limit to integrate the abstract idea into a practical application. Step 2B: Dependent claims recite additional subject matter which, as discussed above with respect to integration of the abstract idea into a practical application, amount to mere instructions to apply an exception. Looking at the limitations as an ordered combination adds nothing that is not already present when looking at the elements taken individually. There is no indication that the combination of elements improves the functioning of a computer or improves any other technology. Their collective functions merely provide conventional computer implementation. Response to Arguments Applicant argues the 101 rejection. The Applicant argues that controlling…. Distribution of the clinical supply based on the supply plan”. Reflects improvement to the technical field of supply distribution for clinical trials. In addition, claim 21 recites a particular solution to the problem of controlling distribution of supplies in a clinical trial. Thus, claim 21 is patent eligible at least improves the technical filed of supply distribution for clinical trials. The Examiner respectfully disagrees. Controlling the distribution of the clinical supply is an extra solution activity. “A transformation that contributes only nominally or insignificantly to the execution of the claimed method (e.g., in a data gathering step or in a field-of-use limitation) would not provide significantly more (or integrate a judicial exception into a practical application). For example, in Mayo the Supreme Court found claims regarding calibrating the proper dosage of thiopurine drugs to be patent ineligible subject matter. The Federal Circuit had held that the step of administering the thiopurine drug demonstrated a transformation of the human body and blood. Mayo, 566 U.S. at 76, 101 USPQ2d at 1967. The Supreme Court disagreed, finding that this step was only a field-of-use limitation and did not provide significantly more than the judicial exception. Id. See MPEP § 2106.05(g) & (h) for more information on insignificant extra-solution activity and field of use, respectively. In addition, the claim does not recite any technical improvement. The claim does not recite any of the following: • An improvement in the functioning of a computer, or an improvement to other technology or technical field, as discussed in MPEP §§ 2106.04(d)(1) and 2106.05(a); • Applying or using a judicial exception to effect a particular treatment or prophylaxis for a disease or medical condition, as discussed in MPEP § 2106.04(d)(2); • Implementing a judicial exception with, or using a judicial exception in conjunction with, a particular machine or manufacture that is integral to the claim, as discussed in MPEP § 2106.05(b); • Effecting a transformation or reduction of a particular article to a different state or thing, as discussed in MPEP § 2106.05(c); and • Applying or using the judicial exception in some other meaningful way beyond generally linking the use of the judicial exception to a particular technological environment, such that the claim as a whole is more than a drafting effort designed to monopolize the exception, as discussed in MPEP § 2106.05(e). Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MAROUN P KANAAN whose telephone number is (571)270-1497. The examiner can normally be reached Monday-Friday 8:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mamon Obeid can be reached on (571) 270-1813. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. MAROUN P. KANAAN Primary Examiner Art Unit 3687 /MAROUN P KANAAN/Primary Examiner, Art Unit 3687
Read full office action

Prosecution Timeline

Jun 28, 2022
Application Filed
Nov 23, 2022
Response after Non-Final Action
May 06, 2023
Non-Final Rejection — §101
Nov 17, 2023
Response Filed
Mar 05, 2024
Final Rejection — §101
Jun 13, 2024
Response after Non-Final Action
Aug 13, 2024
Request for Continued Examination
Aug 14, 2024
Response after Non-Final Action
Nov 30, 2024
Non-Final Rejection — §101
Feb 27, 2025
Applicant Interview (Telephonic)
Feb 27, 2025
Examiner Interview Summary
Apr 04, 2025
Response Filed
Jun 03, 2025
Final Rejection — §101
Jul 07, 2025
Interview Requested
Oct 06, 2025
Request for Continued Examination
Oct 11, 2025
Response after Non-Final Action
Oct 18, 2025
Non-Final Rejection — §101
Jan 22, 2026
Response Filed
Feb 11, 2026
Final Rejection — §101 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12603164
CONTROL APPARATUS, METHOD FOR DISPLAYING DATA LOGS AND MEDICAL CENTRALIZED CONTROL SYSTEM
2y 5m to grant Granted Apr 14, 2026
Patent 12597495
SYSTEM, METHOD, AND APPARATUS FOR AUTOMATING CREATION OF SUBJECTIVE, OBJECTIVE, ASSESSMENT, AND PLAN (SOAP) REPORTS
2y 5m to grant Granted Apr 07, 2026
Patent 12573487
SYSTEMS AND METHODS FOR GENERATING, MANAGING, AND SHARING DIGITAL SCRIPTS
2y 5m to grant Granted Mar 10, 2026
Patent 12573484
SYSTEM AND METHOD FOR AUTOMATICALLY DISPLAYING INFORMATION AT A RADIOLOGIST DASHBOARD
2y 5m to grant Granted Mar 10, 2026
Patent 12567491
STORAGE DEVICES AND OPERATION METHODS THEREOF
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

7-8
Expected OA Rounds
62%
Grant Probability
94%
With Interview (+32.1%)
3y 6m
Median Time to Grant
High
PTA Risk
Based on 701 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month